
Commentary on the model Trustees’ Annual Report and Accounts: 

Triumph for Tomas (T4T). 

T4T had no external activity during this time period due to the global pandemic. We however had to maintain our website and Office 365 subscriptions with a total deduction for the year of (£562) ending the year with a balance for FY20/21 of £12517. 




## **Triumph for Tomas** 

## **Report of the trustees for the year ending 31[st] March 2018.** 

The trustees at T4T present their annual report and accounts for the year end 31[st] March 2019. 

## **Our Aim** 

Our aim is simple, we want to provide factual information to families who have been given PMD as a diagnosis. Enable them to connect with other families and share stories, milestones, advice and feel less isolated and scared. 

## **Our Objective** 

The object of Triumph for Tomas is the promotion and protection of good health among people suffering from Pelizaeus-Merzbacher Disease (PMD) and gene-linked disorders known as the leukodystrophies, characterised by myelin sheath abnormalities, in particular but not exclusively by providing information, advice, practical support and grants of financial assistance to such people and their families and carers. 

## **Review of Activities and Achievements** 

FY18/19 has generated a loss for T4T of £350 once all receipts and payments have been accounted for. T4T did have a disappointing year of activities, however given the minimal global population affected by the conditions we support we do not expect to see large jumps annually. We had a meeting during FY18/19 and discussed our focus for the coming FY19/20 and a real focus on what will help those who can gain support from T4T. 

## **Financial Review** 

FY18/19 all relevant information can be found on our charity accounts CC16a. 



||**Triumph for Tomas**|**Triumph for Tomas**|**Triumph for Tomas**|**1166810**|**1166810**|**1166810**|**CC16a**|
|---|---|---|---|---|---|---|---|
||**For the period**<br>**from**|01/06/2020<br>Period start date|**To**||01/06/2021<br>Period end date|||
|||||||||
|**Section A Receipts and payments**||||||||
|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br> **-**<br>**-**<br>**179**<br>**383**<br>**-**<br>**-**<br>**-**<br>**-**<br> **562**<br>**-**<br>**-**<br> **-**<br>**562**<br>**-                     562**<br>**-**<br>**-**<br>**-                     562**|**Restricted**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**||**Total funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**179**<br>**383**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**562**<br>**-**<br>**-**<br>**-**<br>**562**<br>**-                     562**||**Last year**<br>**to the nearest £**|
|CharityTub Donations|||||||**-**|
||**-**||||||**-**|
||||||||**-**|
|||||||||
||||||||**-**|
||||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
|**_Sub total_**_(Gross income for_<br>_AR)_|**-**||||||**-**|
|||||||||
|**A2 Asset and investment sales,**<br>**(see table).**||||||||
||**-**|||||||
||**-**||||||**-**|
|**_Sub total_**|**-**||||||**-**|
|**_Total receipts_ **<br>**A3 Payments**||||||||
||||||||**-**|
|||||||||
|Postage & Sundries|**-**||||||**-**|
|Windows 365 Subscription|**179**||||||**-**|
|Website Upkeep|**383**||||||**-**|
||||||||**-**|
||||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
|**_Sub total_ **|**562**||||||**-**|
|||||||||
|**A4 Asset and investment**<br>**purchases, (see table)**||||||||
||**-**|||||||
||**-**|||||||
|**_Sub total_ **|**-**||||||**-**|
|**_Total payments_**<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**||||||||
||||||||**-**|
|||||||||
||**-                     562**|**-**|**-**||**-                     562**||**-**|
||**-**|**-**|**-**||**-**||**-**|
||**-**|**-**|**-**||**-**||**-**|
||**-                     562**|**-**|**-**||**-                     562**||**-**|



CCXX R1 accounts (SS) 

31/03/2022 

1 



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>Signed by one or two trustees on<br>behalf of all the trustees<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B5 Liabilities**<br>**B3 Investment assets**|E L Powell<br>Signature<br>M D Powell<br>**Details**<br>**Details**<br>Cash in Bank<br>**Details**<br>**Details**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>**Details**|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**12,517**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**12,517**<br>**-**<br>Agreement Error<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>Matthew Powell<br>Emma Powell|**Endowment**<br>**funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
||M D Powell|Matthew Powell|18.03.2022|
||E L Powell|Emma Powell|**18/03/2022**|



CCXX R2 accounts (SS) 

31/03/2022 

2 

